Citations to this article

Rhabdomyosarcomas do not contain mutations in the DNA binding domains of myogenic transcription factors.
G Anand, … , P S Dickman, E V Prochownik
G Anand, … , P S Dickman, E V Prochownik
Published January 1, 1994
Citation Information: J Clin Invest. 1994;93(1):5-9. https://doi.org/10.1172/JCI116982.
View: Text | PDF
Research Article

Rhabdomyosarcomas do not contain mutations in the DNA binding domains of myogenic transcription factors.

Abstract

Skeletal myogenesis is regulated by a group of transcription factors (MyoD, myogenin, myf5, and myf6) that are "basic helix-loop-helix" proteins that bind to the promoters of muscle-specific genes and promote their expression. We have previously shown that after a mutation of Leu122 to Arg the DNA binding basic domain of MyoD confers c-myc-like functional characteristics to the protein. In this study we used single-strand conformation polymorphism analysis to determine whether such mutations occur naturally in rhabdomyosarcomas. We have found that the basic domains of all the myogenic factors remain unaltered in rhabdomyosarcomas. Selection against such mutations may be the result of functional redundancy of these myogenic transcription factors.

Authors

G Anand, D N Shapiro, P S Dickman, E V Prochownik

×

Total citations by year

Year: 2016 2014 2006 2000 1999 1996 1995 Total
Citations: 2 3 1 2 1 1 1 11
Citation information

Citations to this article (11)

Title and authors Publication Year
MYOD1 (L122R) mutations are associated with spindle cell and sclerosing rhabdomyosarcomas with aggressive clinical outcomes
B Rekhi, P Upadhyay, MP Ramteke, A Dutt 		Modern Pathology 2016
Single nucleotide polymorphisms linked to mitochondrial uncoupling protein genes UCP2 and UCP3 affect mitochondrial metabolism and healthy aging in female nonagenarians
S Kim, L Myers, E Ravussin, KE Cherry, SM Jazwinski 		Biogerontology 2016
A recurrent neomorphic mutation in MYOD1 defines a clinically aggressive subset of embryonal rhabdomyosarcoma associated with PI3K-AKT pathway mutations
S Kohsaka, N Shukla, N Ameur, T Ito, CK Ng, L Wang, D Lim, A Marchetti, A Viale, M Pirun, ND Socci, LX Qin, R Sciot, J Bridge, S Singer, P Meyers, LH Wexler, FG Barr, S Dogan, JA Fletcher, JS Reis-Filho, M Ladanyi 		Nature Genetics 2014
Recurrent MYOD1 mutations in pediatric and adult sclerosing and spindle cell rhabdomyosarcomas: Evidence for a common pathogenesis: MYOD1 Mutation in Rhabdomyosarcoma
NP Agaram, CL Chen, L Zhang, MP LaQuaglia, L Wexler, CR Antonescu 		Genes Chromosomes and Cancer 2014
Transactivating mutation of the MYOD1 gene is a frequent event in adult spindle cell rhabdomyosarcoma: MYOD1 mutation in adult spindle cell rhabdomyosarcoma
K Szuhai, D Jong, WY Leung, CD Fletcher, PC Hogendoorn 		The Journal of Pathology 2014
Principles of Molecular Medicine
MS Runge, C Patterson 		2006
Molecular features of a human rhabdomyosarcoma cell line with spontaneous metastatic progression
FA Scholl, DR Betts, FK Niggli, BW Schäfer 		British Journal of Cancer 2000
The molecular regulation of myogenesis
LA Sabourin, MA Rudnicki 		Clinical Genetics 2000
Human bHLH Transcription Factor GeneMyogenin(MYOG): Genomic Sequence and Negative Mutation Analysis in Patients with Severe Congenital Myopathies
BS Tseng, ST Cavin, EP Hoffman, ST Iannaccone, P Mancias, FW Booth, IJ Butler 		Genomics 1999
Analysis of cyclin-dependent kinase inhibitor genes (CDKN2A, CDKN2B, andCDKN2C) in childhood rhabdomyosarcoma
A Iolascon, MF Faienza, B Coppola, A Rosolen, G Basso, FD Ragione, F Schettini 		Genes, Chromosomes and Cancer 1996
The future of therapy for childhood rhabdomyosarcoma: Clues from molecular biology
LS Constine, RB Marcus, EC Halperin 		International journal of radiation oncology, biology, physics 1995

Advertisement